MaxCyte, Inc. has regained compliance with Nasdaq Listing Rule 5450(a)(1) after its common stock closing bid price was above $1.00 for 10 consecutive business days between May 25, 2026 and June 9, 2026. MaxCyte, Inc. operates in the life sciences industry and provides cell and gene therapy development tools.
